Long-term follow-up of ulcerative colitis patients treated on the basis of their cytomegalovirus antigen status

World Journal of Gastroenterology

Volumn 20, Issue 2, 2014, Pages 509-517

  Inokuchi, Toshihiro ^a   Kato, Jun ^b   Hiraoka, Sakiko ^a   Suzuki, Hideyuki ^a   Nakarai, Asuka ^a   Hirakawa, Tomoko ^a   Akita, Mitsuhiro ^a   Takahashi, Sakuma ^a   Harada, Keita ^a   Okada, Hiroyuki ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cytomegalovirus; Cytomegalovirus antigenemia assay; Ulcerative colitis

Indexed keywords

CALCINEURIN INHIBITOR; CYTOMEGALOVIRUS ANTIGEN PP65; GANCICLOVIR; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIVIRUS AGENT; BIOLOGICAL MARKER; CORTICOSTEROID; GASTROINTESTINAL AGENT; IMMUNOSUPPRESSIVE AGENT; VIRUS ANTIGEN;

ADOLESCENT; ADULT; AGED; APHERESIS; ARTICLE; COLONOSCOPY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; REMISSION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS; BLOOD; CHI SQUARE DISTRIBUTION; CHILD; COLITIS, ULCERATIVE; COLON RESECTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; IMMUNOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RISK; RISK FACTOR; TIME; TREATMENT OUTCOME; VERY ELDERLY; VIRUS ACTIVATION; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CHILD; COLECTOMY; COLITIS, ULCERATIVE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84892854146     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i2.509     Document Type: Article

References (32)

1. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994; 107: 3-11 [PMID: 8020674]
2. Solberg IC, Lygren I, Jahnsen J, Aadland E, Høie O, Cvancarova M, Bernklev T, Henriksen M, Sauar J, Vatn MH, Moum B. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009; 44: 431-440 [PMID: 19101844 DOI: 10.1080/00365520802600961]
3. Höie O, Wolters F, Riis L, Aamodt G, Solberg C, Bernklev T, Odes S, Mouzas IA, Beltrami M, Langholz E, Stockbrügger R, Vatn M, Moum B. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol 2007; 102: 1692-1701 [PMID: 17555460 DOI: 10.1111/j.1572-0241.2007.01265.x]
4. Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Survival and cause-specific mortality in ulcerative colitis: followup of a population-based cohort in Copenhagen County. Gastroenterology 2003; 125: 1576-1582 [PMID: 14724807 DOI: 10.1053/j.gastro.2003.09.036]
5. Kambham N, Vij R, Cartwright CA, Longacre T. Cytomegalovirus infection in steroid-refractory ulcerative colitis: a case-control study. Am J Surg Pathol 2004; 28: 365-373 [PMID: 15104299 DOI: 10.1097/00000478-200403000-00009]
6. Begos DG, Rappaport R, Jain D. Cytomegalovirus infection masquerading as an ulcerative colitis flare-up: case report and review of the literature. Yale J Biol Med 1996; 69: 323-328 [PMID: 9273986]
7. Al-Zafiri R, Gologan A, Galiatsatos P, Szilagyi A. Cytomegalovirus complicating inflammatory bowel disease: a 10-year experience in a community-based, university-affiliated hospital. Gastroenterol Hepatol (N Y) 2012; 8: 230-239 [PMID: 22723754]
8. Domènech E, Vega R, Ojanguren I, Hernández A, Garcia-Planella E, Bernal I, Rosinach M, Boix J, Cabré E, Gassull MA. Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy. Inflamm Bowel Dis 2008; 14: 1373-1379 [PMID: 18452205 DOI: 10.1002/ibd.20498]
9. Kishore J, Ghoshal U, Ghoshal UC, Krishnani N, Kumar S, Singh M, Ayyagari A. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol 2004; 53: 1155-1160 [PMID: 15496396 DOI: 10.1099/jmm.0.45629-0]
10. Matsuoka K, Iwao Y, Mori T, Sakuraba A, Yajima T, Hisamatsu T, Okamoto S, Morohoshi Y, Izumiya M, Ichikawa H, Sato T, Inoue N, Ogata H, Hibi T. Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. Am J Gastroenterol 2007; 102: 331-337 [PMID: 17156136 DOI: 10.1111/j.1572-0241.2006.00989.x]
11. Nguyen M, Bradford K, Zhang X, Shih DQ. Cytomegalovirus Reactivation in Ulcerative Colitis Patients. Ulcers 2011; 2011: pii: 282507 [PMID: 21731826 DOI: 10.1155/2011/282507]
12. Hommes DW, Sterringa G, van Deventer SJ, Tytgat GN, Weel J. The pathogenicity of cytomegalovirus in inflammatory bowel disease: a systematic review and evidence-based recommendations for future research. Inflamm Bowel Dis 2004; 10: 245-250 [PMID: 15290919 DOI: 10.1097/00054725-2004050 00-00011]
13. Dimitroulia E, Spanakis N, Konstantinidou AE, Legakis NJ, Tsakris A. Frequent detection of cytomegalovirus in the intestine of patients with inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 879-884 [PMID: 16954807]
14. Eyre-Brook IA, Dundas S. Incidence and clinical significance of colonic cytomegalovirus infection in idiopathic inflammatory bowel disease requiring colectomy. Gut 1986; 27: 1419-1425 [PMID: 3026932]
15. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, Mitton S, Orchard T, Rutter M, Younge L, Lees C, Ho GT, Satsangi J, Bloom S. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60: 571-607 [PMID: 21464096 DOI: 10.1136/gut.2010.224154]
16. Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 2012; 6: 965-990 [PMID: 23040452 DOI: 10.1016/ j.crohns.2012.09.003]
17. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501-523; quiz 524 [PMID: 20068560 DOI: 10.1038/ajg.2009.727]
18. Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander? Inflamm Bowel Dis 2010; 16: 1620-1627 [PMID: 20232408 DOI: 10.1002/ ibd.21275]
19. Mori T, Mori S, Kanda Y, Yakushiji K, Mineishi S, Takaue Y, Gondo H, Harada M, Sakamaki H, Yajima T, Iwao Y, Hibi T, Okamoto S. Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 33: 431-434 [PMID: 14676775 DOI: 10.1038/sj.bmt.1704369]
20. Nagata N, Kobayakawa M, Shimbo T, Hoshimoto K, Yada T, Gotoda T, Akiyama J, Oka S, Uemura N. Diagnostic value of antigenemia assay for cytomegalovirus gastrointestinal disease in immunocompromised patients. World J Gastroenterol 2011; 17: 1185-1191 [PMID: 21448424 DOI: 10.3748/wjg.v17. i9.1185]
21. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063-4071 [PMID: 8916975]
22. Kanda Y, Yamashita T, Mori T, Ito T, Tajika K, Mori S, Sakura T, Hara M, Mitani K, Kurokawa M, Akashi K, Harada M. A randomized controlled trial of plasma real-time PCR and antigenemia assay for monitoring CMV infection after unrelated BMT. Bone Marrow Transplant 2010; 45: 1325-1332 [PMID: 19966850 DOI: 10.1038/bmt.2009.337]
23. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-1845 [PMID: 8196726 DOI: 10.1056/ NEJM199406303302601]
24. Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D'Haens G, D'Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6: 991-1030 [PMID: 23040451 DOI: 10.1016/j.crohns.2012.09.002]
25. Suzuki H, Kato J, Kuriyama M, Hiraoka S, Kuwaki K, Yama-moto K. Specific endoscopic features of ulcerative colitis complicated by cytomegalovirus infection. World J Gastroenterol 2010; 16: 1245-1251 [PMID: 20222169 DOI: 10.3748/wjg.v16. i10.1245]
26. TRUELOVE SC, WITTS LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2: 1041-1048 [PMID: 13260656]
27. Papadakis KA, Tung JK, Binder SW, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol 2001; 96: 2137-2142 [PMID: 11467645 DOI: 10.1111/j.1572-0241.2001.03949.x]
28. Cottone M, Pietrosi G, Martorana G, Casà A, Pecoraro G, Oliva L, Orlando A, Rosselli M, Rizzo A, Pagliaro L. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol 2001; 96: 773-775 [PMID: 11280549 DOI: 10.1111/j.1572-0241.2001.03620.x]
29. Yoshino T, Nakase H, Ueno S, Uza N, Inoue S, Mikami S, Matsuura M, Ohmori K, Sakurai T, Nagayama S, Hasegawa S, Sakai Y, Chiba T. Usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies. Inflamm Bowel Dis 2007; 13: 1516-1521 [PMID: 17828781 DOI: 10.1002/ibd.20253]
30. Roblin X, Pillet S, Oussalah A, Berthelot P, Del Tedesco E, Phelip JM, Chambonnière ML, Garraud O, Peyrin-Biroulet L, Pozzetto B. Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. Am J Gastroenterol 2011; 106: 2001-2008 [PMID: 21788989 DOI: 10.1038/ajg.2011.202]
31. Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D'Haens G, Domènech E, Eliakim R, Eser A, Frater J, Gassull M, Giladi M, Kaser A, Lémann M, Moreels T, Moschen A, Pollok R, Reinisch W, Schunter M, Stange EF, Tilg H, Van Assche G, Viget N, Vucelic B, Walsh A, Weiss G, Yazdanpanah Y, Zabana Y, Travis SP, Colombel JF. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3: 47-91 [PMID: 21172250 DOI: 10.1016/ j.crohns.2009.02.010]
32. Pillet S, Pozzetto B, Jarlot C, Paul S, Roblin X. Management of cytomegalovirus infection in inflammatory bowel diseases. Dig Liver Dis 2012; 44: 541-548 [PMID: 22538204 DOI: 10.1016/j.dld.2012.03.018